Safety and efficacy of Saroglitazar magnesium in live donor liver transplant recipients in preventing Non-alcoholic fatty liver disease (NAFLD): a pilot randomized placebo-controlled trial double- blinded trial. - Nil

Amrita Institute Of Medical Sciences Research Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1. Adults >18 <75 years of age.
•2. Patients who are at least 6 months post-transplant with normal liver function but are diabetic and have either diabetes mellitus, dyslipidemia and hypertriglyceridemia or obesity
•3. History of medical compliance with immunosuppression.

•Patient with abnormal transaminases due to
•a.Biopsy proven rejection
•b.Clinical rejection
•c.Vascular complication
•d.Biliary complication
•Patients with graft dysfunction due to any cause
•Body mass index (BMI) <18 kg/mÂ².
•History of myopathies or evidence of active muscle diseases.
•Unstable cardiovascular disease.
•History of bladder disease and/or hematuria or has current hematuria unless due to a urinary tract infection.
•Active malignancy post-liver transplantation.
•History of malignancy in the past 5 years and/or active neoplasm.
•History of chronic rejection of liver transplant graft.
•History of alcohol intake.
•Subject tests positive for a urine drug screen.
•Pregnant or lactating females.

发起方